Sellas Life Sciences is trading 4.19% down at $13.50 as investor skepticism grows around an unconfirmed report that the Phase 3 REGAL leukemia trial reached its 80th event.
- Sellas has not confirmed the milestone; its latest disclosed count remains 78 events, leaving the rally vulnerable to profit-taking and disappointment.
- The decline despite biotech sector strength suggests company-specific trial uncertainty, not broad market weakness.
- Confidence is medium because coverage identifies the setup, but no formal company announcement directly attributes the move.